Tag Archives: systemic

Drug Regulators Publish Draft Guidance on Development, Analysis and Presentaion of Microbological Data for Systemic Antibarterial Drugs

Drug Regulators, FDA, Publish Guidance For Systemic Antibaterial Agents

Full Text Here

The purpose of this guidance is to inform industry of the Food and Drug Administration’s (FDA’s) current thinking regarding the types of microbiological studies, assessments, and clinical trials needed to support an investigational new drug application (IND) and a new drug application (NDA) for a systemic antibacterial drug product. This guidance is intended to serve as a focus for continued discussions among the Office of Antimicrobial Products, pharmaceutical sponsors and applicants, the academic community, and the public. Recommendations in this guidance cover three major areas: (1) conducting general nonclinical studies; (2) conducting animal and human studies and clinical trials; and (3) establishing and updating in vitro susceptibility test methods, quality control parameters, and interpretive criteria. This guidance also recommends the content and format for presentation of microbiological data for antibacterial drug products in the Microbiology subsection of labeling.
This guidance does not address the development of antiviral, antifungal, antiparasitic, or antimycobacterial agents or antibacterials administered by nonsystemic routes (e.g., topical). This guidance is not meant to provide details on clinical trial design.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

ida 100programme 515x64 LowRes Drug Regulators Publish Draft Guidance on Development, Analysis and Presentaion of Microbological Data for Systemic Antibarterial Drugs

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

Grow your Expertise for Free

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

First name

E-mail address

This guideline ap
recombinant vaccines for the prevention and treatment of infectious disease, and provides guidance on quality, non-clinical and clinical aspects.
ida consultants freestrategyconsultation 515x64 Drug Regulators Publish Draft Guidance on Development, Analysis and Presentaion of Microbological Data for Systemic Antibarterial Drugs